US › Healthcare

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

US · Healthcare · Biotechnology

$0.58-4.92%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.8M

EPS

$-2.75

EPS estimate

$0.65

EPS came in at -2.75 against a street estimate of 0.65 — a miss of 523.1%.

Key statistics

Market cap

$1.6M

Forward P/E

0.0

P/B

0.97

Book value

$2.00

EPS (TTM)

$-9.44

52-week high

$9.82

52-week low

$0.58

50-day MA

$1.90

200-day MA

$8.02

Analyst view

with an average price target of $12.00.

Shareholding

Insiders

39.47%

Institutions

6.02%

Largest institutional holders

Fund	Stake
Marex Group Ltd	2.03%
HRT FINANCIAL LLC	1.89%
UBS Group AG	0.17%
Tower Research Capital LLC	0.03%
Advisor Group Holdings, Inc.	0.01%
Ronald Blue Trust, Inc.	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lakewood-Amedex Biotherapeutics Inc. Common Stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.